-- Humanwell Healthcare (SHA:600079) unit has secured U.S. Food and Drug Administration approval for its generic version of the fertility drug cetrorelix acetate injection.
The injection is a fertility treatment used to prevent premature luteinizing hormone surges in women undergoing controlled ovarian stimulation, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company declined 1% in recent trade.